Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nal-irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinib
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This appears to be a hypothetical combination of five drugs that are not documented as being used together in clinical practice. The individual components have different applications: nal-irinotecan (liposomal irinotecan), 5-fluorouracil, and leucovorin are used in combination for pancreatic cancer, while benmelstobart and anlotinib have been studied together with chemotherapy for small cell lung cancer.
02
Targets
TOP1 (DNA Topoisomerase I)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on nal-irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nal-irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinib.